GlassScriptPhysician profile
Jennifer Channual
NPI 1689986374
$3,691.36
in general payments reported to CMS, 2019-2025
28 companies · $186 in 2025
The $186 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $244 · 2020: $212 · 2021: $592 · 2022: $1,137 · 2023: $1,161 · 2024: $158 · 2025: $186.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,397 · Education: $99.99 · Travel and Lodging: $8.92.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,396.64 |
| Education | $99.99 |
| Travel and Lodging | $8.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $699.47 | 2021-2025 | Olumiant, Ebglyss, Taltz |
| Pfizer INC. | $634.20 | 2019-2023 | |
| Galderma Laboratories, L.P. | $433.96 | 2019-2025 | Oracea, Epsolay, Aklief |
| Incyte Corporation | $246.79 | 2021-2023 | Opzelura |
| Janssen Biotech, INC. | $234.86 | 2021-2023 | Tremfya, Stelara, Remicade |
| Merz North America, INC. | $229.17 | 2019-2023 | Xeomin |
| Mentor Worldwide LLC | $133.33 | 2023 | Mentor Memorygel Resterilizable Gel Sizer |
| Allergan, INC. | $124.74 | 2019-2022 | |
| Genzyme Corporation | $112.67 | 2022-2023 | |
| Abbvie INC. | $104.22 | 2024-2025 | |
| Almirall LLC | $75.82 | 2022 | |
| Leo Pharma INC. | $72.49 | 2019-2022 | |
| Epi Health, LLC | $61.79 | 2021-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $56.81 | 2019-2021 | |
| Dermira, INC. | $53.49 | 2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Revance Therapeutics, INC. | $52.11 | 2024 | Daxxify |
| Sun Pharmaceutical Industries INC. | $51.39 | 2022-2023 | Winlevi |
| Regeneron Healthcare Solutions, INC. | $47.93 | 2023 | Dupixent |
| Arcutis Biotherapeutics, INC. | $43.40 | 2023 | |
| Sanofi-Aventis U.S. LLC | $40.49 | 2021 | |
| Amgen INC. | $37.26 | 2023 | Otezla |
| Mayne Pharma Commercial LLC | $30.59 | 2020-2023 | |
| Biofrontera INC. | $26.55 | 2023-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Novartis Pharmaceuticals Corporation | $26.18 | 2025 | |
| Journey Medical Corporation | $19.95 | 2022 | |
| Vyne Pharmaceuticals INC. | $14.79 | 2020 | |
| Nabriva Therapeutics, Plc | $14.75 | 2022 | |
| Prugen, INC. Pharmaceuticals | $12.16 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Channual listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.